Combinatorial inhibition of MEK/ERK and γ-secretase increases efficacy in melanoma, papillary thyroid cancer, and CRC (Krepler et al., 2016, Yamashita et al., 2013, Schmidt et al., 2018). This evidence concerns the gene MAP2K7 and melanoma.